<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01364623</url>
  </required_header>
  <id_info>
    <org_study_id>TBS-2-2011-01</org_study_id>
    <nct_id>NCT01364623</nct_id>
  </id_info>
  <brief_title>PK Study of Testosterone Nasal Gel (TBS-2) in Healthy Premenopausal Women</brief_title>
  <official_title>An Open-label, Single and Multiple Application of Intranasal Testosterone Gel (TBS-2) in Healthy Premenopausal Female Subjects at Three Dose Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acerus Pharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acerus Pharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess the bioavailability of total testosterone through
      pharmacokinetic profiles obtained following (a) single administration of three doses of TBS-2
      b) multiple administration TBS-2.

      In addition, assessing the bioavailability of free testosterone, dihydrotestosterone, SHBG
      and estradiol through pharmacokinetic profiles was also conducted.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 2 Period study that requires overnight stays in clinic. Blood samples are required
      at all visits including sampling at predefined time periods during the overnight stays.

      Period I

      Subjects were checked-in on Day 1 Period I to start their baseline testosterone measurement
      (dependant on menstrual cycle, preferably within 48hr of start of the menstrual cycle). They
      remained institutionalized until Day 4 morning, and were checked out after the 48 hour blood
      draw and study close-out for those that did not continue with Period II.

      Period II (Multi-Dose)

      At the end of Period 1, a total of 8 subjects sampled from these 3 cohorts, who were willing
      and able to continue with the multiple-dose portion of the study were selected to participate
      in Period 2. Subjects were institutionalized starting on Day 1 of Visit 3 until Day 5 morning
      of Visit 3, and were checked out after the 48 hour blood draw and study close-out.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability (AUC0-t) of Total Testosterone Through Pharmacokinetic (PK) Profiles</measure>
    <time_frame>Based on blood samples collected -0.25, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 16, 20, 23.5h relative to dosing</time_frame>
    <description>Area under the concentration time curve from time zero to the last measurable concentration time point (AUC0-t) for single dose and AUCtau shown for multiple dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bioavailability (Cmax) of Total Testosterone Through Pharmacokinetic Profiles</measure>
    <time_frame>Based on blood samples collected -0.25, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 16, 20, 23.5h relative to dosing</time_frame>
    <description>Cmax - maximum concentration of total testosterone observed after dosing of TBS-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medium Dose TBS-2 Multiple Dose Average Steady-state Concentration (Cavg) of Total Testosterone</measure>
    <time_frame>-0.25, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 16, 20, 24, 32, 40, 48h after Day 3 dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) for Dihydrotestosterone Following TBS-2</measure>
    <time_frame>Based on blood samples collected -0.25, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 16, 20, 23.5h relative to dosing</time_frame>
    <description>AUCt shown for single dose and AUCtau for multiple dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC) for Estradiol Following TBS-2</measure>
    <time_frame>Based on blood samples collected -0.25, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 16, 20, 23.5h relative to dosing</time_frame>
    <description>AUCt shown for single dose and AUCtau for multiple dose.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Female Sexual Dysfunction</condition>
  <arm_group>
    <arm_group_label>Low dose TBS-2 single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TBS-2 dispensers prefilled with 0.24% testosterone gel to deliver a single dose of 300 μg of testosterone per nostril, for a total dose of 600 μg given at 0800 hours (±30 minutes) on Day 2 of Period 1 for Cohort 1 (Low dose testosterone nasal gel, single dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose TBS-2 single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TBS-2 dispensers prefilled with 0.48% testosterone gel to deliver a single dose of 600 μg of testosterone per nostril, for a total dose of 1200 μg given at 0800 hours (±30 minutes) on Day 2 of Period 1 for Cohort 2 (Medium dose testosterone nasal gel, single dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose TBS-2 single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TBS-2 dispensers prefilled with 0.72% testosterone gel to deliver a single dose of 900 μg of testosterone per nostril, for a total dose of 1800 μg given at 0800 hours (±30 minutes) on Day 2 of Period 1 for Cohort 3 (High dose testosterone nasal gel, single dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose TBS-2 multiple doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TBS-2 dispensers prefilled with 0.48% testosterone gel to deliver a single dose of 600 μg of testosterone per nostril, for a total dose of 1200 μg given t.i.d. daily at 0800 hours (± 30 minutes), 1600 hours (± 30 minutes), and 2400 hours (± 30 minutes) on Days 1 and 2 of Period 2, and once in the morning at 0800 hours (± 30 minutes) on Day 3 of Period 2 (Multi-dose group) (Medium dose testosterone nasal gel, multiple dose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose testosterone nasal gel, single dose</intervention_name>
    <description>Low dose testosterone nasal gel, single dose</description>
    <arm_group_label>Low dose TBS-2 single dose</arm_group_label>
    <other_name>TBS-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medium dose testosterone nasal gel, single dose</intervention_name>
    <description>Medium dose testosterone nasal gel, single dose</description>
    <arm_group_label>Medium dose TBS-2 single dose</arm_group_label>
    <other_name>TBS-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose testosterone nasal gel, single dose</intervention_name>
    <description>High dose testosterone nasal gel, single dose</description>
    <arm_group_label>High dose TBS-2 single dose</arm_group_label>
    <other_name>TBS-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medium dose testosterone nasal gel, multiple dose</intervention_name>
    <description>Medium dose testosterone nasal gel, multiple dose</description>
    <arm_group_label>Medium dose TBS-2 multiple doses</arm_group_label>
    <other_name>TBS-2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Subjects having regular menstrual cycles between 26-32 days.

          -  Women of childbearing potential must agree to use one of the following reliable birth
             control methods prior to the study, during the study and up until one month after the
             end of the study:

               -  Surgically sterile

               -  Intrauterine device in place for at least 3 months prior to study initiation

               -  Barrier method (condom with spermicidal agent use by partner)

               -  Abstinence

          -  Negative for drugs of abuse, hepatitis B-surface antigen, hepatitis C, HIV, and
             pregnancy (serum ß-HCG).

          -  Body Mass Index greater than or equal to 18.5 kg/m² and less than or equal to 35
             kg/m².

          -  Subjects with a normal ENT exam.

          -  Subjects with normal TSH values.

          -  No clinically significant findings in the physical examination, 12-lead ECG and vital
             signs

          -  Normal thyroid function. Physiological prolactin concentration.

          -  All clinical laboratory test values within the acceptable ranges (any clinically
             significant findings will require investigator/sponsor approval)

          -  Able to understand and provide written informed consent.

          -  Availability of the subject for the entire study period and willingness of the subject
             to adhere to protocol requirements, as evidenced by a signed ICF

        Exclusion Criteria

          -  Known history of hypersensitivity to Testosterone (e.g. Intrinsa patch) and/or related
             drugs.

          -  Known history of polycystic ovarian syndrome.

          -  Known history or presence of cardiac, pulmonary, gastrointestinal, endocrine,
             musculoskeletal, neurological, psychiatric, hematological, reproductive, liver or
             kidney disease, unless judged not clinically significant by the Principal Investigator
             or medical designate.

          -  Presence of or known history of Estrogen-responsive tumors such as breast cancer and
             /or history of any cancer, excluding basal cell carcinoma.

          -  Known history of frequent clinically significant acne.

          -  Known history of hirsutism

          -  History of nasal surgery, specifically turbinoplasty, septoplasty, rhinoplasty, &quot;nose
             job&quot;, or sinus surgery.

          -  Prior nasal fractures.

          -  Active allergies, such as rhinitis, rhinorrhea, and nasal congestion.

          -  Mucosal inflammatory disorders, specifically pemphigus, and Sjogren's syndrome.

          -  Sinus disease, specifically acute sinusitis, chronic sinusitis, or allergic fungal
             sinusitis.

          -  History of nasal disorders or sleep apnea.

          -  Use of any form of intra-nasal medication delivery, specifically nasal corticosteroids
             and oxymetazoline containing nasal sprays

          -  History of Hepatitis B, a positive test for Hepatitis B surface antigen, a history of
             Hepatitis C, a positive test for Hepatitis C antibody, a history of HIV infection or
             demonstration of HIV antibodies.

          -  Any history of severe allergic reaction (including drugs, food, insect bites,
             environmental allergens or any condition known to interfere with the absorption,
             distribution, metabolism or excretion of drugs.

          -  Any history of drug abuse or alcohol abuse as per DSM-IV criteria within 6 months of
             study drug administration.

          -  Current treatment with any hormone replacement therapy within previous 12 months,
             treatment with drugs which interfere with metabolism of Testosterone within 30 days of
             study drug administration and/or any other prescription medications. Difficulty in
             abstaining from OTC medication for the duration of study.

          -  Use of oral, transdermal and implant contraceptives within 30 days prior to drug
             administration or a depot contraceptives injection within one year prior to drug
             administration.

          -  Evidence of pregnancy or lactation.

          -  Subjects who are breast feeding or have breast fed within the last six (6) months
             prior to the Screening Visit.

          -  Administration of another investigational drug within 30 days prior to study
             medication administration.

          -  Blood donation within 56 days prior to study medication administration.

          -  Any participation as a plasma donor in a plasmapheresis program within seven days
             preceding screening in this study.

          -  Intolerance to venipuncture.

          -  History of abnormal bleeding tendencies or thrombophlebitis unrelated to venipuncture
             or intravenous cannulation.

          -  History of Deep Venous Thrombosis or coagulation disorders.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalia Tkachenko, MD</last_name>
    <role>Study Director</role>
    <affiliation>Trimel Pharmaceuticals Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Premier Research International LLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 27, 2011</study_first_submitted>
  <study_first_submitted_qc>June 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2011</study_first_posted>
  <results_first_submitted>March 9, 2018</results_first_submitted>
  <results_first_submitted_qc>August 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 13, 2019</results_first_posted>
  <last_update_submitted>October 4, 2019</last_update_submitted>
  <last_update_submitted_qc>October 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>testosterone</keyword>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low Dose TBS-2 Single Dose</title>
          <description>Low dose testosterone nasal gel: Single dose administration</description>
        </group>
        <group group_id="P2">
          <title>Medium Dose TBS-2 Single Dose</title>
          <description>Medium dose testosterone nasal gel: Single dose administration</description>
        </group>
        <group group_id="P3">
          <title>High Dose TBS-2 Single Dose</title>
          <description>High dose testosterone nasal gel: single dose administration</description>
        </group>
        <group group_id="P4">
          <title>Medium Dose TBS-2 Multiple-Dose</title>
          <description>High dose testosterone nasal gel: multiple dose administration</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Single Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Multiple Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Dose TBS-2</title>
          <description>Low dose testosterone nasal gel: Single dose administration</description>
        </group>
        <group group_id="B2">
          <title>Medium Dose TBS-2</title>
          <description>Medium dose testosterone nasal gel: Single dose administration
Medium dose testosterone nasal gel: Multiple dose administration</description>
        </group>
        <group group_id="B3">
          <title>High Dose TBS-2</title>
          <description>High dose testosterone nasal gel: Single dose administration</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.5" spread="5.73"/>
                    <measurement group_id="B2" value="29.8" spread="4.43"/>
                    <measurement group_id="B3" value="27.0" spread="6.57"/>
                    <measurement group_id="B4" value="29.8" spread="5.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bioavailability (AUC0-t) of Total Testosterone Through Pharmacokinetic (PK) Profiles</title>
        <description>Area under the concentration time curve from time zero to the last measurable concentration time point (AUC0-t) for single dose and AUCtau shown for multiple dose.</description>
        <time_frame>Based on blood samples collected -0.25, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 16, 20, 23.5h relative to dosing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose TBS-2 Single Dose</title>
            <description>Low dose testosterone nasal gel: Single dose administration</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose TBS-2 Single Dose</title>
            <description>Medium dose testosterone nasal gel: Single dose administration</description>
          </group>
          <group group_id="O3">
            <title>High Dose TBS-2 Single Dose</title>
            <description>High dose testosterone nasal gel: single dose administration</description>
          </group>
          <group group_id="O4">
            <title>Medium Dose TBS-2 Multiple-Dose</title>
            <description>Medium dose testosterone nasal gel: Multiple dose administration</description>
          </group>
        </group_list>
        <measure>
          <title>Bioavailability (AUC0-t) of Total Testosterone Through Pharmacokinetic (PK) Profiles</title>
          <description>Area under the concentration time curve from time zero to the last measurable concentration time point (AUC0-t) for single dose and AUCtau shown for multiple dose.</description>
          <units>ng*h/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.981" spread="39"/>
                    <measurement group_id="O2" value="328.002" spread="35.8"/>
                    <measurement group_id="O3" value="834.391" spread="49.7"/>
                    <measurement group_id="O4" value="553.325" spread="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Bioavailability (Cmax) of Total Testosterone Through Pharmacokinetic Profiles</title>
        <description>Cmax - maximum concentration of total testosterone observed after dosing of TBS-2</description>
        <time_frame>Based on blood samples collected -0.25, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 16, 20, 23.5h relative to dosing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose TBS-2 - Single Dose</title>
            <description>Low dose testosterone nasal gel: Single dose administration</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose TBS-2 - Single Dose</title>
            <description>Medium dose testosterone nasal gel: Single dose Administration</description>
          </group>
          <group group_id="O3">
            <title>High Dose TBS-2 - Single Dose</title>
            <description>High dose testosterone nasal gel: single dose Administration</description>
          </group>
          <group group_id="O4">
            <title>Medium Dose TBS-2 - Multiple Dose</title>
            <description>Medium dose testosterone nasal gel: multiple dose administration</description>
          </group>
        </group_list>
        <measure>
          <title>Bioavailability (Cmax) of Total Testosterone Through Pharmacokinetic Profiles</title>
          <description>Cmax - maximum concentration of total testosterone observed after dosing of TBS-2</description>
          <units>ng/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.058" spread="61.1"/>
                    <measurement group_id="O2" value="62.880" spread="48.6"/>
                    <measurement group_id="O3" value="113.912" spread="44.3"/>
                    <measurement group_id="O4" value="137.555" spread="41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Medium Dose TBS-2 Multiple Dose Average Steady-state Concentration (Cavg) of Total Testosterone</title>
        <time_frame>-0.25, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 16, 20, 24, 32, 40, 48h after Day 3 dosing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Medium Dose TBS-2 - Multiple Dose</title>
            <description>Medium dose testosterone nasal gel - multiple dose administration:
A total dose of 1200 μg given t.i.d. daily at 0800 hours (± 30 minutes), 1600 hours (± 30 minutes), and 2400 hours (± 30 minutes) on Days 1 and 2 of Period 2, and once in the morning at 0800 hours (± 30 minutes) on Day 3 of Period 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Medium Dose TBS-2 Multiple Dose Average Steady-state Concentration (Cavg) of Total Testosterone</title>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.944" spread="0.408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC) for Dihydrotestosterone Following TBS-2</title>
        <description>AUCt shown for single dose and AUCtau for multiple dose.</description>
        <time_frame>Based on blood samples collected -0.25, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 16, 20, 23.5h relative to dosing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose TBS-2 - Single Dose</title>
            <description>Low dose testosterone nasal gel: Single dose administration</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose TBS-2 - Single Dose</title>
            <description>Medium dose testosterone nasal gel: Single dose Administration</description>
          </group>
          <group group_id="O3">
            <title>High Dose TBS-2 - Single Dose</title>
            <description>High dose testosterone nasal gel: single dose Administration</description>
          </group>
          <group group_id="O4">
            <title>Medium Dose TBS-2 - Multiple Dose</title>
            <description>Medium dose testosterone nasal gel: multiple dose administration</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC) for Dihydrotestosterone Following TBS-2</title>
          <description>AUCt shown for single dose and AUCtau for multiple dose.</description>
          <units>ng*h/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.515" spread="74.9"/>
                    <measurement group_id="O2" value="38.457" spread="49.1"/>
                    <measurement group_id="O3" value="85.180" spread="64.2"/>
                    <measurement group_id="O4" value="122.194" spread="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve (AUC) for Estradiol Following TBS-2</title>
        <description>AUCt shown for single dose and AUCtau for multiple dose.</description>
        <time_frame>Based on blood samples collected -0.25, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 16, 20, 23.5h relative to dosing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose TBS-2 - Single Dose</title>
            <description>Low dose testosterone nasal gel: Single dose administration</description>
          </group>
          <group group_id="O2">
            <title>Medium Dose TBS-2 - Single Dose</title>
            <description>Medium dose testosterone nasal gel: Single dose Administration</description>
          </group>
          <group group_id="O3">
            <title>High Dose TBS-2 - Single Dose</title>
            <description>High dose testosterone nasal gel: single dose Administration</description>
          </group>
          <group group_id="O4">
            <title>Medium Dose TBS-2 - Multiple Dose</title>
            <description>Medium dose testosterone nasal gel: multiple dose administration</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve (AUC) for Estradiol Following TBS-2</title>
          <description>AUCt shown for single dose and AUCtau for multiple dose.</description>
          <units>pg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.763" spread="118.7"/>
                    <measurement group_id="O2" value="75.97" spread="82.2"/>
                    <measurement group_id="O3" value="43.97" spread="197.9"/>
                    <measurement group_id="O4" value="400.264" spread="54.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Low Dose TBS-2 Single Dose</title>
          <description>Low dose testosterone nasal gel: Single dose administration</description>
        </group>
        <group group_id="E2">
          <title>Medium Dose TBS-2 Single Dose</title>
          <description>Medium dose testosterone nasal gel: Single dose Administration</description>
        </group>
        <group group_id="E3">
          <title>High Dose TBS-2 Single Dose</title>
          <description>High dose testosterone nasal gel: single dose Administration</description>
        </group>
        <group group_id="E4">
          <title>Medium Dose TBS-2 Multiple Dose</title>
          <description>Medium dose testosterone nasal gel: multiple dose administration</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Catheter site hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Catheter site inflammation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Catheter site phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Vulvitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nasal mucosal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rhinalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nathan Bryson, Vice President, Scientific Affairs</name_or_title>
      <organization>Acerus Pharmaceuticals Corporation</organization>
      <phone>1-416-679-0776</phone>
      <email>nbryson@aceruspharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

